Navigation Links
Hospira Announces Certain Preliminary Third-Quarter 2011 Results

LAKE FOREST, Ill., Oct. 18, 2011 /PRNewswire/ -- Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, today announced that its preliminary third-quarter 2011 net sales, adjusted* income from operations and adjusted* earnings per share are lower than anticipated primarily due to certain quality actions taken in response to a U.S. Food and Drug Administration (FDA) 2010 warning letter and subsequent observations related to the company's manufacturing facility in Rocky Mount, North Carolina, and device quality and supply-related issues.

"While recently launched product sales continue to drive top-line growth, we were extremely disappointed in the third quarter by developments related to our quality-improvement initiatives that resulted in a significant slowdown of production and an associated impact on our operating performance," said F. Michael Ball, chief executive officer. "As I indicated at our Investor Day in early September, addressing these issues is Hospira's top priority, and our organization is committed to full resolution. I remain confident that Hospira will emerge from this process a stronger, more competitive global company that is optimally positioned to serve the needs of our customers and patients, and deliver strong value to our shareholders."

Preliminary net sales for the quarter were $977 million, an increase of 2.9 percent compared to $949 million in the third quarter of 2010, with the increase primarily driven by continued strong U.S. net sales of the oncolytic docetaxel. On a constant-currency basis, third-quarter net sales increased slightly compared to the third quarter of 2010.

Preliminary adjusted* income from operations for the third quarter of 2011 was $142 million compared to $189 million in the third quarter of 2010. The decline is primarily due to charges and costs associated with the quality actions and related inventory losses. Preliminary adjusted* diluted earnings per share were $0.66 for the third quarter of 2011.  

On a U.S. Generally Accepted Accounting Principles (GAAP) basis, the company had a preliminary loss from operations of $85 million in the third quarter of 2011 compared to income from operations of $142 million in the third quarter of 2010. The third quarter of 2011 includes a preliminary goodwill impairment charge related to Hospira's European operating unit identified during Hospira's annual impairment test.  On a GAAP basis, the company had a preliminary diluted loss per share of $0.54 compared to diluted earnings per share of $0.42 in the prior-year third quarter. Results under GAAP include items as detailed in the schedule attached to this press release.

Preliminary cash flow from operations for the first nine months of 2011 was $277 million, compared to the $235 million generated for the same period in 2010.  The increase primarily reflects the timing of chargeback and rebate payments.  

These results are preliminary and remain subject to change as the company completes its quarterly close and reporting processes. Hospira intends to issue a full press release containing the third-quarter 2011 results on our originally scheduled conference call date of October 26, 2011.  

2011 Projections Given the preliminary third-quarter results, Hospira currently estimates that its adjusted* diluted earnings per share for full-year 2011 will range between $2.95 and $3.05 per share, or $1.40 to $1.50 on a GAAP basis. These estimates are preliminary. Hospira will discuss its full-year 2011 projections in further detail when it reports its final third-quarter 2011 results on October 26, 2011.

*Use of Non-GAAP Financial MeasuresAdjusted measures used in this press release are reconciled to the most comparable measures calculated in accordance with GAAP in the schedules attached to this release. For more information regarding these non-GAAP financial measures, please see Hospira's Current Report on Form 8-K furnished to the Securities and Exchange Commission on the date of this press release.

WebcastHospira will hold a conference call for investors and media at 9 a.m. Central time today, October 18, 2011. A simultaneous webcast of the conference call will be available on Hospira's website at Listeners should log on approximately 10 minutes in advance to ensure proper setup for receiving the webcast.

About Hospira
Hospira, Inc. is the world's leading provider of injectable drugs and infusion technologies. Through its broad, integrated portfolio, Hospira is uniquely positioned to Advance Wellness™ by improving patient and caregiver safety while reducing healthcare costs. The company is headquartered in Lake Forest, Ill., and has approximately 14,000 employees. Learn more at

Private Securities Litigation Reform Act of 1995 --
A Caution Concerning Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including projections of certain measures of Hospira's results of operations, projections of certain charges and expenses, and statements regarding Hospira's goals and strategy. Hospira cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, regulatory, legal, technological, manufacturing supply, quality and other factors that may affect Hospira's operations and may cause actual results to be materially different from expectations include the risks, uncertainties and factors discussed under the headings "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Hospira's latest Annual Report on Form 10-K and subsequent Forms 10-Q, filed with the Securities and Exchange Commission, which are incorporated by reference. Hospira undertakes no obligation to release publicly any revisions to forward-looking statements as the result of subsequent events or developments.Hospira, Inc.Reconciliation of GAAP to Non-GAAP Financial Measures(Unaudited)(dollars in millions, except for per share amounts)Three months ended September 30, 2011 Reconciliation of GAAP to Non-GAAP Financial Measures:(Loss) Income
From OperationsDiluted EPS (1)GAAP financial measures$
(0.54)Specified item:   Amortization and impairment of certain intangible assets

34.40.14   Certain quality and product related charges

36.70.14   Capacity expansion related charges

1.50.01   Goodwill impairment (A)

155.00.92   Diluted shares impact(0.01)Adjusted financial measures (2)

.66GAAP results for the three months ended September 30, 2011 include:(A) Goodwill impairment: $155.0 million reported in Restructuring, impairment and (gain) on disposition of assets, net related to Hospira'sEurope, Middle East & Africa reporting unit.Three months ended September 30, 2010 Reconciliation of GAAP to Non-GAAP Financial Measures:Income From
OperationsDiluted EPS (1)GAAP financial measures

.42Specified items:   Project Fuel and related charges

6.70.02   Facilities Optimization charges

3.70.02   Amortization of certain intangible assets

16.20.07   Certain quality and product related charges

15.10.05   Acquisition and integration-related charges

5.90.02   Loss on early debt extinguishment

-0.14Adjusted financial measures (2)


Adjusted Diluted EPS are shown net of tax for the three months ended September 30, 2011 and 2010, based on the statutory tax rate in the varioustax jurisdictions in which the adjustments occurred.(2)

The Non-GAAP financial measures contained in this press release (including adjusted income from operations and adjusted diluted EarningsPer Share) adjust for certain specified items. All Non-GAAP financial measures are intended to supplement the applicable GAAP measures andshould not be considered in isolation from, or a replacement for, financial measures prepared in accordance with GAAP.Hospira, Inc.Reconciliation of GAAP to Non-GAAP Financial Measures(Unaudited)(dollars in millions, except for per share amounts)Preliminary Reconciliation of GAAP to Adjusted Diluted Earnings Per Share Projection for Full Year 2011:Preliminary EPS Projection (1)GAAP financial measure

$ 1.40


.50Adjustments:   Project Fuel and related charges0.04   Facilities Optimization charges 0.01   Estimated $95 million for the amortization and impairment   of intangible assets related to certain acquisitions0.38   Estimated charges related to certain quality- and  product-related matters (mid-point of an estimated range of $0.25 to $0.31 per diluted share)0.28   Estimated charges related to capacity expansion0.03   Restructuring charges related to certain Latin America distributor operations0.03   Goodwill impairment0.90   Tax benefits from the first-quarter 2011 U.S. income tax audit settlement(0.12)Adjusted financial measure (3)

$ 2.95


3.05Reconciliation of GAAP to Adjusted Diluted Earnings Per Share for Full Year 2010:Actual EPS (2)GAAP financial measure$
2.11Specified items:   Project Fuel and related charges0.09   Facilities Optimization charges 0.07   Amortization of certain intangible assets0.28   Certain quality and product related charges 0.20   Acquisition and integration-related charges 0.07   Impairment of certain assets 0.12   Research and development charges 0.18   Litigation settlement and related charges 0.05   Loss on early debt extinguishment0.14Adjusted financial measure (3)$

Adjusted EPS is shown net of expected tax of approximately $72 million, calculated based on the statutory tax rates in the various jurisdictionsin which the specified items are expected to occur, exclusive of the tax-audit settlement.(2)

Adjusted EPS is shown net of tax of $106.8 million related to specified items, calculated based on the statutory tax rates in the variousjurisdictions in which the specified items occurred.(3)

The Non-GAAP financial measures contained in this press release (including adjusted income from operations andadjusted diluted Earnings Per Share) adjust for certain specified items. All Non-GAAP financial measures are intended to supplement theapplicable GAAP measures and should not be considered in isolation from, or a replacement for, financial measures prepared in accordancewith GAAP. Refer to Hospira’s filing on Form 8-K filed on October 18, 2011 for additional information.

SOURCE Hospira, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Hospira to Host Conference Call for Third-Quarter 2011 Results
2. Hospira Announces Positive Results From Phase I U.S. Clinical Trial of Biosimilar Erythropoietin in Renal Patients
3. Hospira to Host 2011 Investor Day
4. Hospira to Present at the Morgan Stanley Global Healthcare Conference
5. Hospira Expands Board of Directors
6. Hospira Announces U.S. Approval of Solution Version of Gemcitabine Injection
7. Hospira Reports Second-Quarter 2011 Results
8. Hospira to Host Conference Call for Second-Quarter 2011 Results
9. Hospira Receives Health Canada Regulatory Approval for Symbiq™ Infusion System Software Upgrade
10. Hospira to Present at the Sanford C. Bernstein Twenty-Seventh Annual Strategic Decisions Conference 2011
11. Hospira Highlights Progress in 2010 at Its 2011 Annual Meeting of Shareholders
Post Your Comments:
(Date:10/13/2015)...  Graduate students across the country, with an ... soon have the opportunity to learn about a ... discovery and development process. Eli Lilly and Company ... leaders from academic institutions to create an elective ... Drug Development."  Lilly will formally unveil the eLearning ...
(Date:10/13/2015)... SAN FRANCISCO , October 13, 2015 ... expected to reach USD 26.8 billion by 2022, according ... Anesthesia and respiratory devices, owing to their capability to ... expected to witness a substantial growth. --> ... reach USD 26.8 billion by 2022, according to a ...
(Date:10/13/2015)... , Oct. 13, 2015   Micell Technologies ... DESSOLVE I and II trials of its MiStent Sirolimus ... ® ) were presented at the 27th Annual ... San Francisco , October 11-15. TCT ... cardiovascular medicine. MiStent SES was designed to optimize vessel ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... 13, 2015 , ... The Lymphoma Research Foundation (LRF) – ... serving the lymphoma community through a comprehensive series of education programs, outreach initiatives ... Commitment to Cure last night at the Mandarin Oriental in New York City. ...
(Date:10/13/2015)... ... October 13, 2015 , ... The documentary Pink & Blue: Colors ... Beverly Hills October 2 - 8, coinciding with National Hereditary Breast & Ovarian Cancer ... takes us through the lives of women - and men - who are dealing ...
(Date:10/13/2015)... ... October 13, 2015 , ... Purdue University ... the Life Sciences Initiative aimed at enhancing Purdue’s life sciences research and graduate ... True” capital campaign. , The investment will result in cohesive efforts across several ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... ... enterprise focused on cancer patients, today announced a new partnership with the ... battling this rare type of non-Hodgkin’s lymphoma, their families and physicians. , ...
(Date:10/13/2015)... Diego, CA (PRWEB) , ... October 13, 2015 ... ... launch of its newest technology platform, ENGAGE, at HIMSS’s Patient Engagement Summit ... to end. , ENGAGE delivers innovative health programs and interventions via mobile devices ...
Breaking Medicine News(10 mins):